Are there any international models we should look at in terms of initial implementation of pharmacare? While we have heard many times that going with a fully universal model of pharmacare would save money in the long term, there must be ways to keep the initial price tag down, in terms of transitioning to the new model. What countries do you think of when you think of properly implementing this for the first time?
On May 2nd, 2016. See this statement in context.